## TROW: T. Rowe Price Group, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 0.9% below STRENGTH zone (3.0-6.0%); PEG 4.90 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. T. Rowe Price Group (NASDAQ:TROW) Price Target Raised to $128.00**
- Source: MarketBeat | 20251217T144308 | Neutral | Relevance: 100%
- Morgan Stanley raised its price target for T. Rowe Price Group (NASDAQ:TROW) to $128.00 from $126.00, reiterating an "equal weight" rating, which suggests a potential upside of approximately 21.8% from the current share price. Despite this, the overall analyst sentiment remains cautious, with a consensus price target of $108.85 and a "Reduce" rating from MarketBeat, based on 12 Hold and 4 Sell ratings. T. Rowe Price recently exceeded earnings expectations, reporting an EPS of $2.81 against an estimate of $2.55 and revenue of $1.89 billion, a 6% year-over-year increase.

**2. Keefe, Bruyette & Woods Cuts Price Target on T. Rowe to $115 From $117, Maintains Market Perform Rating**
- Source: marketscreener.com | 20251216T120839 | Somewhat-Bearish | Relevance: 100%
- Keefe, Bruyette & Woods has reduced its price target for T. Rowe Price Group (TROW) to $115 from the previous $117. The firm has, however, maintained its "Market Perform" rating for the investment management company. This adjustment reflects an updated outlook by the analyst firm on T. Rowe's valuation.

**3. Goldman, T. Rowe Launch First Co-Branded Portfolio for Wealthy Clients**
- Source: TradingView — Track All Markets | 20251216T170849 | Somewhat-Bearish | Relevance: 97%
- Goldman Sachs Asset Management and T. Rowe Price have launched their first co-branded model portfolios, marking the initial phase of their strategic alliance. These portfolios, offered through GeoWealth’s UMA platform, are designed for mass-affluent and high-net-worth clients, leveraging the expertise of both firms. A fifth model, the "Goldman Sachs T. Rowe Price High Net Worth Portfolio," is anticipated in early 2026.

**4. Global Asset Allocation: The View From Europe**
- Source: T. Rowe Price | 20251216T200826 | Neutral | Relevance: 94%
- This article provides a December 2025 outlook on global asset allocation, moving to a slightly positive view across global risk assets due to favorable earnings trends and economic growth, supported by fiscal and monetary policies. Key themes driving positioning include the potential outperformance of small-cap stocks and concerns over fiscal experiments leading to rising long-term bond yields, particularly in Japan. The report highlights that while AI-driven growth remains significant, there's growing alignment for small-caps and a cautious stance on global long-term bond yields.

**5. Corient Private Wealth LLC Sells 3,030 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251216T100558 | Somewhat-Bullish | Relevance: 74%
- Corient Private Wealth LLC reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 2.5%, selling 3,030 shares, though it still holds 117,474 shares valued at $63 million. Despite this sale, institutional ownership remains high at 87.84% due to other large investors significantly increasing their holdings. IDEXX Laboratories reported a strong earnings beat and positive revenue, with a "Moderate Buy" consensus analyst rating and a price target of $763.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Keefe, Bruyette | $115 | $117 | -2% |
| 2025-12-17 | Morgan Stanley | $128 | $126 | +2% |
| 2025-12-12 | Barclays | $102 | $101 | +1% |
| 2025-12-05 | Evercore ISI Gr | $115 | $118 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Keefe, Bruyette | main | Market Perform |
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Barclays | main | Underweight |
| 2025-12-05 | Evercore ISI Gr | main | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 19 ($0.32M) |
| Sells | 15 ($7.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.1%)
- Blackrock Inc.: 9.4% (-1.6%)
- State Street Corpora: 6.5% (-2.7%)
- Charles Schwab Inves: 3.6% (+1.1%)
- Geode Capital Manage: 2.8% (+1.0%)

### Key Risks

1. Insider selling cluster: $8.0M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Elevated short interest (8.8%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.90 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROA 10%, margin 29%). Balance sheet: strong liquidity (11.4x), low leverage (D/E 0.26). Insider selling cluster ($8.0M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $22.7B |
| Beta | 1.54 |
| 52W Range | $77.85 - $118.32 |
| Short Interest | 8.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.90 |
| Forward P/E | 10.0 |
| Current P/E | 10.6 |
| YoY Growth | 5.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 50. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.89% (CS: 48) | Neutral |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | -0.01 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.039x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $103.32
- **Stop Loss:** $99.02 (4.2% risk)
- **Target:** $107.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 165
- **Position Value:** $17,047.80
- **Portfolio %:** 17.05%
- **Risk Dollars:** $712.50
- **Risk Per Trade:** 0.71%
- **Modifiers:** L1 95% | L2 75% | Combined 0.71x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-06 (Est: $2.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.54 | $2.81 | +10.5% |
| 2025Q2 | $2.13 | $2.24 | +4.9% |
| 2025Q1 | $2.13 | $2.23 | +4.7% |
| 2024Q4 | $2.21 | $2.12 | -4.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*